PDCD1 and colorectal carcinoma: In addition, ICB targeting these ICPs, such as PD1-blocking antibodies, pembrolizumab, and nivolumab, have shown efficacy in patients with metastatic MSI-H CRC, and they have been granted accelerated FDA approval [7].